Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 5:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 10,853 matching trials from the live ClinicalTrials.gov search.

Filters: Columbus, Ohio Clear all

Conditions: Cardiac Arrest (CA)
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 37 Weeks to 18 Years
Enrollment: 1,620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 22
States / cities: Orange, California • Stanford, California • Denver, Colorado + 18 more

Conditions: Leukemia
Interventions: sargramostim; Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 120 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 15
States / cities: Phoenix, Arizona • Oakland, California • Miami Beach, Florida + 12 more

Conditions: Acute Lymphoblastic Leukemia/Lymphoma, Myelodysplasia, Acute Myelogenous Leukemia, Juvenile Myelomonocytic Leukemia, Chronic Myelogenous Leukemia
Interventions: Not listed
Lead sponsor: Center for International Blood and Marrow Transplant Research; Network
Eligibility: Up to 22 Years
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 32
States / cities: Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 27 more

Conditions: Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: zoledronic acid, quality-of-life assessment; Drug · Procedure
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 55
States / cities: Birmingham, Alabama • Springdale, Arkansas • Gilroy, California + 48 more

Conditions: Obstructive Sleep Apnea
Interventions: Survey; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Carotid Artery Disease, Carotid Stenosis, Stroke, Atherosclerosis
Interventions: Carotid artery stenting with filter (interventional), Carotid artery endarterectomy (surgical); Device · Procedure
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 1,663 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 62
States / cities: Phoenix, Arizona • Mountain View, California • Newport Beach, California + 52 more

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: AZD0120, Daratumumab, Dexamethasone, Isatuximab, Lenalidomide, Bortezomib, Cyclophosphamide, Fludarabine; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 45
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more

Conditions: Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
Interventions: SAR443579; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 1 Year and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 7 more

Conditions: Contraceptive Usage
Interventions: Norethindrone Acetate; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,659 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 53
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 50 more

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma
Interventions: Zilovertamab vedotin, Nemtabrutinib; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 20
States / cities: Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 15 more

Conditions: Recurrent Plasma Cell Myeloma
Interventions: Dexamethasone, HDAC Inhibitor AR-42, Laboratory Biomarker Analysis, Pomalidomide; Drug · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44
Interventions: AOC 1044; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 7 Years to 27 Years · Male only
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 10
States / cities: Little Rock, Arkansas • La Jolla, California • Sacramento, California + 7 more

Conditions: Diabetes Mellitus, Type 2
Interventions: semaglutide, oral glucose-lowering medications (commercially available); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: Alhambra, California • Costa Mesa, California • La Jolla, California + 20 more

Conditions: Relapsed/Refractory Systemic Light Chain Amyloidosis
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2035
U.S. locations: 8
States / cities: Duarte, California • Denver, Colorado • Boston, Massachusetts + 5 more

Conditions: Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Lumbar Puncture, Magnetic Resonance Imaging; Procedure · Device
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Leiomyoma
Interventions: BAY1002670, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 36
States / cities: Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo, Background PAH Therapy; Biological · Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years and older
Enrollment: 324 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 39
States / cities: Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more

Conditions: Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions: cabozantinib, prednisone; Drug
Lead sponsor: Exelixis; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 77
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 73 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions: Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 22
States / cities: Los Angeles, California • Pasadena, California • Aurora, Colorado + 13 more

Conditions: Diabetes Mellitus, Type 2
Interventions: BI 10773 placebo, BI 10773 low dose, BI 10773 high dose; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 494 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 50 more

Conditions: Aortic Stenosis
Interventions: Medtronic TAV, Edwards TAV; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years to 105 Years
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 71
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 58 more

Conditions: Graft vs. Host Disease
Interventions: Brentuximab Vedotin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Boston, Massachusetts • New York, New York • Columbus, Ohio

Conditions: Multiple Myeloma
Interventions: Dexamethasone, Daratumumab, Bortezomib, Iberdomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 939 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 43
States / cities: Hot Springs, Arkansas • Cerritos, California • Fountain Valley, California + 38 more

Conditions: Aortic Aneurysm, Abdominal
Interventions: IMPEDE-FX RapidFill Implants, EndoVascular Aneurysm Repair; Device · Procedure
Lead sponsor: Shape Memory Medical, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 32 more

Search by objective public record fields.

Physiology-directed Epinephrine Dosing in Pediatric Cardiac Arrest

Sargramostim in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission Following Initial Treatment

Natural History and Biology of Long-Term Late Effects Following Hematopoietic Cell Transplant for Childhood Hematologic Malignancies

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

Can Postoperative Outcomes be Predicted From Asking OSA Screening Questions Pre-operatively?

Carotid Angioplasty and Stenting Versus Endarterectomy in Asymptomatic Subjects Who Are at Standard Risk for Carotid Endarterectomy With Significant Extracranial Carotid Stenotic Disease (ACT I)

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping

A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes

REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE

Brentuximab Vedotin for Steroid Refractory GvHD

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion